Clinical Trial Update: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacodynamics, pharmacokinetics, safety and tolerability of ultra-low doses of dapagliflozin in healthy subjects; the trial reports P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED